Esperion Says FDA Stance Means No Clear Regulatory Path For ETC-1002

Esperion Therapeutics and the FDA have failed to reach agreement on a definitive approval path for the company's cholesterol drug ETC-1002, raising the possibility of a long and more expensive development pathway for the oral therapy.

Barrier

Esperion Therapeutics Inc. had been working with the FDA in an attempt to forge a new regulatory path for its cholesterol drug ETC-1002 in statin-intolerant patients, a population the US agency has been very cautious about in the past.

The Ann Arbor, Michigan-based group had proposed a plan to conduct a Phase III study using LDL-C lowering as a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from New Products

More from Scrip